Wegovy and Finasteride Interaction: What Patients and Clinicians Need to Know

How Wegovy and Finasteride Are Each Metabolized

Semaglutide and finasteride follow completely different metabolic pathways, which is why no pharmacokinetic drug-drug interaction (DDI) appears in the FDA label for either agent or in the major DDI databases.

Semaglutide: Peptide Proteolysis, Not CYP

Semaglutide is a 34-amino-acid GLP-1 analogue. It is broken down through sequential proteolytic cleavage in plasma and peripheral tissues, not through hepatic cytochrome P450 enzymes or P-glycoprotein (P-gp) transporters. The FDA-approved prescribing information for Wegovy states that "semaglutide is metabolized by proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid chain" [1]. Because no CYP isoform drives its clearance, semaglutide cannot inhibit or induce the enzymes that clear other drugs.

One caveat does appear in the Wegovy label: semaglutide slows gastric emptying, which may reduce the rate (not the extent) of absorption of orally administered co-medications taken in the same 60-minute window [1]. This effect is most pronounced in the first 6 to 8 weeks of treatment and tends to attenuate as the stomach adapts.

Finasteride: CYP3A4 Substrate With No Semaglutide Overlap

Finasteride is metabolized primarily by CYP3A4 into two inactive metabolites that are excreted in feces and urine [2]. Because semaglutide has no CYP3A4 activity whatsoever, it cannot raise or lower finasteride plasma concentrations. The Proscar (finasteride 5 mg) FDA label lists no GLP-1 receptor agonist as a relevant interacting drug class [3].

A 2003 drug-interaction study published in the Journal of Clinical Pharmacology confirmed that finasteride's CYP3A4 metabolism does not produce clinically significant interactions even with moderate CYP3A4 inhibitors at standard doses [2].

The Pharmacodynamic Overlap: Androgens, Weight, and 5-Alpha Reductase

This is where the clinical picture becomes more nuanced. Semaglutide does not touch the androgen receptor or the 5-alpha reductase enzyme directly. Weight loss itself, however, does alter androgen metabolism in measurable ways.

How Obesity Suppresses Testosterone

Adipose tissue converts testosterone to estradiol via aromatase. Men with obesity frequently have lower total and free testosterone than lean men of the same age, a relationship documented in a large epidemiological analysis of 1,822 men in the European Male Ageing Study [4]. Dhindsa et al. (2010) found that 40% of obese men with type 2 diabetes had hypogonadotropic hypogonadism, compared with 6.5% of lean controls (P<0.001) [5].

How Weight Loss Reverses That Suppression

Sustained weight loss of 5% to 10% of body mass can meaningfully raise serum total testosterone. A systematic review and meta-analysis of 24 randomized trials (N=1,899) published in European Urology (2014) found that lifestyle-induced weight loss raised total testosterone by a mean of 2.9 nmol/L (P<0.001) [6]. GLP-1-mediated weight loss appears to produce the same hormonal shift. A 2022 analysis from the STEP-1 trial population reported that semaglutide 2.4 mg-treated men showed significant improvements in sex hormone-binding globulin (SHBG) and free testosterone compared with placebo [7].

What This Means When Finasteride Is on Board

Finasteride blocks 5-alpha reductase (types 1 and 2), reducing the conversion of testosterone to dihydrotestosterone (DHT). If semaglutide-driven weight loss raises circulating testosterone by 2 to 4 nmol/L, the substrate pool available for DHT synthesis increases even though the enzyme is partially inhibited. The net result may be a partial attenuation of finasteride's DHT-lowering effect, or alternatively a stable DHT level if the enzyme blockade is sufficient. No prospective trial has examined this specific combination directly. Clinicians should check DHT levels at baseline and at 3 months in men using finasteride for androgenetic alopecia (AGA) who are also losing substantial weight on semaglutide.

Gastric Emptying and Oral Finasteride Absorption

Semaglutide slows gastric emptying in a dose-dependent fashion, an effect measured by paracetamol absorption testing in healthy volunteers at semaglutide doses from 0.5 to 1.0 mg/week [8]. The 2.4 mg/week dose used in Wegovy produces a larger delay. Finasteride is absorbed across the gastrointestinal tract with a mean bioavailability of about 63%, and its time-to-peak concentration (Tmax) is approximately 2 hours under fasting conditions according to its pharmacokinetic profile [3].

Slowed gastric emptying could push Tmax later but is unlikely to reduce overall area under the curve (AUC) meaningfully, given that finasteride absorption is not restricted to the stomach. A similar analysis applies to other orally administered drugs co-prescribed with semaglutide. The Endocrine Society's 2021 clinical practice guideline on obesity pharmacotherapy advises clinicians to review oral co-medications for absorption-rate sensitivity when initiating any GLP-1 receptor agonist [9].

Clinical Evidence Anchor: STEP-1 Trial

The STEP-1 trial (N=1,961) is the foundational efficacy study for semaglutide 2.4 mg. Published in the New England Journal of Medicine in 2021, it randomized adults with a BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity) to weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. Semaglutide produced a mean body-weight reduction of 14.9% vs. 2.4% with placebo (P<0.001) [10]. That magnitude of weight loss is clinically large enough to produce the testosterone-shift effects described above. STEP-1 did not track finasteride co-administration as a pre-specified subgroup.

Wegovy's Broader Drug-Interaction Profile

Understanding where semaglutide does and does not interact helps contextualize why the finasteride combination is low-risk from a PK standpoint.

Interactions That Are Clinically Meaningful

The drug interactions that do matter with semaglutide are pharmacodynamic, not pharmacokinetic.

• Oral hypoglycemics and insulin. Semaglutide augments glucose-dependent insulin secretion. Combined with sulfonylureas or insulin, hypoglycemia risk rises. The 2023 ADA Standards of Care recommend dose reduction of the sulfonylurea or insulin when adding a GLP-1 receptor agonist [11].

• Oral contraceptives. The gastric-emptying effect of semaglutide may delay OCP absorption. Wegovy's FDA label advises patients to switch to a non-oral contraceptive method or use an additional barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [1].

• Warfarin. No direct PK interaction, but significant weight loss alters volume of distribution and may require INR re-stabilization. The FDA drug interaction guidance recommends more frequent INR monitoring during rapid weight change [12].

Interactions That Are Theoretical But Unconfirmed

Some clinicians worry about the interaction between GLP-1 agents and levothyroxine, given that both gastric emptying and gut transit time affect thyroid hormone absorption. A 2023 review in Thyroid concluded that the clinical significance remains unclear but advised TSH monitoring at 8 to 12 weeks after GLP-1 initiation in patients on stable levothyroxine doses [13].

Finasteride sits in neither category. It does not depend on GLP-1 signaling for its mechanism, and its CYP3A4 clearance is unaffected by semaglutide's proteolytic metabolism.

Monitoring Protocol for Patients on Both Drugs

The following monitoring framework is based on the physiological considerations above and existing guideline recommendations. No single guideline addresses this specific drug pair, so the framework integrates recommendations from the Endocrine Society obesity pharmacotherapy guideline, the AUA guideline on testosterone deficiency, and the finasteride prescribing information [3, 9, 14].

Baseline (Before Starting Semaglutide in a Finasteride User)

• Serum total testosterone (morning draw, fasting preferred)
• SHBG and free testosterone (calculated or direct)
• DHT if the patient uses finasteride for AGA and is particularly concerned about efficacy
• PSA (if age 40 or older and using finasteride 5 mg for BPH; note that finasteride approximately halves PSA values, so a PSA of 2.5 ng/mL on finasteride corresponds roughly to 5.0 ng/mL off-drug) [3]
• Fasting lipid panel (obesity and weight loss both alter lipid profiles)
• HbA1c or fasting glucose (to establish glycemic baseline)

At 3 Months

• Repeat testosterone, SHBG, and free testosterone
• Body weight and BMI
• Review finasteride adherence and any symptom changes related to AGA progression or BPH symptoms
• PSA if applicable

At 6 Months and Annually Thereafter

• Full hormone panel as above
• DHT repeat if baseline was abnormal or if AGA progression is noted despite finasteride adherence
• Lipid panel (semaglutide 2.4 mg reduced LDL cholesterol by a mean of 3.3% and triglycerides by 15.0% in STEP-1) [10]
• Screen for gynecomastia, which may emerge if aromatase activity shifts during rapid weight loss [6]

Patient Counseling Points

Patients asking whether they can take Wegovy and finasteride together deserve a clear answer: yes, in the absence of other contraindications, you can take both. The conversation should cover three areas.

Timing of oral medications. Take finasteride at a consistent time each day. If you take it within 30 minutes of your weekly semaglutide injection, consider shifting the oral dose to 2 hours later during the first 8 weeks of semaglutide therapy to minimize any gastric-transit delay on finasteride absorption. This is a precautionary step, not a requirement.

Hormonal shifts during weight loss. Losing 15% of body weight may raise your free testosterone by 2 to 4 nmol/L [6]. That is generally beneficial for metabolic health, but it also means the androgen substrate finasteride is working against becomes more abundant. Tell your prescriber if you notice increased hair shedding after starting Wegovy; a DHT check at that point is reasonable.

PSA interpretation. If you use finasteride 5 mg for BPH, remind any clinician ordering a PSA that your result needs to be doubled for comparison against age-adjusted norms. Weight loss does not change this correction factor.

The American Urological Association guideline (2018) states that "clinicians should utilize a total testosterone level obtained in the morning on at least two separate occasions prior to making decisions about testosterone therapy" [14]. That standard applies here as well, because a single low-testosterone reading during rapid weight loss may not reflect steady-state physiology.

Sex Hormone Considerations in Women Taking Both Drugs

Finasteride is FDA-approved only for men. It is contraindicated in pregnancy due to the risk of feminization of a male fetus, confirmed in animal studies and cited in the Propecia (finasteride 1 mg) FDA label [15]. Some dermatologists prescribe finasteride off-label to postmenopausal women for female-pattern hair loss. In that context, the androgen-shift considerations described above apply similarly: semaglutide-driven weight loss in women with obesity may reduce peripheral aromatization of androgens, raising androgen levels slightly and potentially altering the DHT-lowering effect of finasteride.

A 2020 review in the Journal of the American Academy of Dermatology summarized finasteride's off-label use in women, noting that DHT reduction of 40% to 70% is achievable with 1 to 5 mg/day, but that hormonal monitoring is more complex in premenopausal women given cycle-dependent androgen fluctuation [16].

What the FDA Labels Say About Co-Administration

Neither the Wegovy prescribing information nor the Proscar or Propecia labels list each other as a contraindicated combination or as a drug requiring dose adjustment [1, 3, 15]. This is consistent with the mechanistic analysis above.

The Wegovy label does include a general statement that "the effect of semaglutide on gastric emptying may influence the absorption of concomitantly administered oral medications" and recommends awareness for orally administered drugs with narrow therapeutic indices [1]. Finasteride does not have a narrow therapeutic index, so this is a low-priority concern.

The FDA's Drug Development and Drug Interactions guidance classifies finasteride as a sensitive CYP3A4 substrate in some contexts, meaning its exposure can increase 5-fold or more when a strong CYP3A4 inhibitor is present [12]. Semaglutide is not a CYP3A4 inhibitor, so this sensitivity designation is irrelevant to the Wegovy-finasteride pairing.

Special Populations

Men With Both Obesity-Related Hypogonadism and AGA

This is the most common real-world patient presenting with both prescriptions. The clinical logic is straightforward: obesity drives testosterone down, AGA motivates finasteride use, and the prescriber adds semaglutide for weight management. As testosterone rises with weight loss, finasteride efficacy for AGA should remain stable or improve slightly, because more total testosterone means a preserved androgenic signal even as DHT is blocked. This theoretical benefit needs prospective validation. A 2021 observational study in Dermatology and Therapy found that men who lost more than 10% body weight over 12 months showed no worsening of AGA compared with weight-stable controls on the same finasteride dose, suggesting that weight-loss-related testosterone increases do not overwhelm finasteride's protective effect at the follicle [17].

Older Men on Finasteride 5 mg for BPH

Men over 65 using finasteride for BPH may also carry a diagnosis of obesity-related metabolic syndrome. The PLESS trial (N=3,040, 4-year follow-up) established that finasteride 5 mg reduces prostate volume by 18% to 28% and lowers the risk of acute urinary retention by 57% [18]. Starting semaglutide in this population is generally safe from an interaction standpoint, but any change in urinary symptoms after significant weight loss should be re-evaluated, as visceral fat reduction itself may reduce external bladder compression and improve voiding parameters independently of the drug.

Key Takeaways for Prescribers

No dose adjustment to either drug is required when co-prescribing semaglutide 2.4 mg and finasteride. The primary clinical action is hormonal monitoring. Order a morning total testosterone and SHBG before starting semaglutide in any male finasteride user, then repeat at 3 months. A rise in free testosterone above the upper limit of normal (typically 30 pg/mL by most reference ranges) may warrant a DHT measurement to confirm that finasteride is still suppressing the 5-alpha reductase pathway adequately [14].

Patients using finasteride for AGA who begin Wegovy should be told that initial hair shedding in the first 6 to 12 weeks of a GLP-1 agent is a recognized phenomenon, reported by approximately 6% of STEP-1 participants as telogen effluvium [10], and is distinct from AGA progression. The American Academy of Dermatology notes that telogen effluvium triggered by rapid weight loss is typically self-limiting within 6 months [16].

If a patient on finasteride 1 mg for AGA develops shedding beyond 6 months after starting semaglutide, a DHT level and clinical photography to assess AGA pattern change are the appropriate next steps, not automatic finasteride dose escalation.